Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
At 15.10 PM IST, the barometer index, the S&P BSE Sensex jumped 199.88 points or 0.25% to 81,227.90. The Nifty 50 index rose 6.35 points or 0.03% to 25,036.60.
The broader market outperformed the frontline indices. The BSE 150 MidCap Index gained 0.42% and the BSE 250 SmallCap Index added 1.39%.
The market breadth was strong. On the BSE, 3,161 shares rose and 798 shares fell. A total of 215 shares were unchanged.
Buzzing Index:
The Nifty Pharma index jumped 1.47% to 28,402.90. The index jumped 4.79% in the four consecutive trading sessions.
Divis Laboratories (up 5.11%), Piramal Pharma (up 2.85%), Sun Pharmaceutical Industries (up 2.6%), Wockhardt (up 2.32%) and Abbott India (up 0.93%) were the top gainers. Among the other gainers were Laurus Labs (up 0.79%), Ajanta Pharma (up 0.49%), Torrent Pharmaceuticals (up 0.49%), Biocon (up 0.44%) and Zydus Lifesciences (up 0.43%).
Stocks in Spotlight:
Tega Industries advanced 1.67%. The company reported a consolidated net loss of Rs 47.4 crore in Q2 FY27 as against a net profit of Rs 44.94 crore posted in Q2 FY26. The company's revenue from operations surged to Rs 4,254.04 crore in Q2 FY27 from Rs 405.35 crore in Q2 FY26.
Finolex Cables surged 19.21% after reporting strong Q2 FY27 results, with consolidated net profit rising 67.8% YoY to Rs 272.92 crore from Rs 162.64 crore in Q2 FY26. On a sequential basis, net profit increased 9.6% from Rs 249.04 crore in Q1 FY27. Revenue from operations rose 65.0% YoY to Rs 2,269.33 crore from Rs 1,375.79 crore. Sequentially, revenue increased 12.7% from Rs 2,013.15 crore.
Revenue from operations rose 35.4% YoY to Rs 3,676 crore from Rs 2,715 crore. Sequentially, revenue increased 19.4% from Rs 3,080 crore.
Profit before tax increased 65.0% YoY to Rs 1,505 crore from Rs 912 crore. Sequentially, PBT rose 27.5% from Rs 1,180 crore.
Total expenditure increased 16.1% YoY to Rs 2,252 crore from Rs 1,940 crore. Cost of raw materials consumed rose 93.4% to Rs 1,812 crore from Rs 937 crore. Employee expenses increased 25.4% to Rs 444 crore from Rs 354 crore. Interest costs rose 62.5% to Rs 13 crore, while depreciation increased 25.7% to Rs 142 crore from Rs 113 crore.
The company reported a foreign exchange gain of Rs 24 crore in Q2 FY27, compared with a gain of Rs 63 crore in the corresponding quarter last year.
Consolidated net cash inflow from operating activities stood at Rs 384 crore during H1 FY27, lower than Rs 1,645 crore in H1 FY26.
Divi's Laboratories is engaged in the manufacture of active pharmaceutical ingredients (APIs), intermediates and nutraceutical ingredients.
Divis Laboratories Ltd is up for a fifth straight session today. The stock is quoting at Rs 9811, up 1.52% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.72% on the day, quoting at 23102.8. The Sensex is at 74685.25, up 0.72%. Divis Laboratories Ltd has gained around 6.08% in last one month.
Meanwhile, Nifty Pharma index of which Divis Laboratories Ltd is a constituent, has gained around 3.43% in last one month and is currently quoting at 26710.8, up 1.88% on the day. The volume in the stock stood at 6.02 lakh shares today, compared to the daily average of 5.93 lakh shares in last one month.
The benchmark November futures contract for the stock is quoting at Rs 9844.5, up 1.12% on the day. Divis Laboratories Ltd is up 45.61% in last one year as compared to a 10.18% slide in NIFTY and a 22.72% slide in the Nifty Pharma index.
The PE of the stock is 85.56 based on TTM earnings ending June 26.
Divis Laboratories Ltd rose for a third straight session today. The stock is quoting at Rs 9616.5, up 1.17% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.19% on the day, quoting at 22705.75. The Sensex is at 73291.61, down 0.42%. Divis Laboratories Ltd has added around 1.97% in last one month.
Meanwhile, Nifty Pharma index of which Divis Laboratories Ltd is a constituent, has added around 1.54% in last one month and is currently quoting at 26267.25, up 0.96% on the day. The volume in the stock stood at 5.07 lakh shares today, compared to the daily average of 5.95 lakh shares in last one month.
The benchmark November futures contract for the stock is quoting at Rs 9664.5, up 1.8% on the day. Divis Laboratories Ltd is up 47.67% in last one year as compared to a 12.85% fall in NIFTY and a 18.23% fall in the Nifty Pharma index.
The PE of the stock is 83.99 based on TTM earnings ending June 26.
Divis Laboratories Ltd is down for a fifth straight session today. The stock is quoting at Rs 9175.5, down 0.79% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is up around 0.25% on the day, quoting at 22478.35. The Sensex is at 72073.15, up 0.23%.Divis Laboratories Ltd has lost around 1.5% in last one month.Meanwhile, Nifty Pharma index of which Divis Laboratories Ltd is a constituent, has eased around 2.14% in last one month and is currently quoting at 26311.55, down 0.79% on the day. The volume in the stock stood at 2.71 lakh shares today, compared to the daily average of 5.21 lakh shares in last one month.
The benchmark October futures contract for the stock is quoting at Rs 9215, down 0.56% on the day. Divis Laboratories Ltd jumped 57.48% in last one year as compared to a 10.37% slide in NIFTY and a 19.85% spurt in the Nifty Pharma index.
The PE of the stock is 82.36 based on TTM earnings ending June 26.
Divis Laboratories Ltd is down for a fifth straight session today. The stock is quoting at Rs 9108.5, down 0.97% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is up around 0.65% on the day, quoting at 23269.55. The Sensex is at 74441.9, up 0.59%.Divis Laboratories Ltd has added around 7.39% in last one month.Meanwhile, Nifty Pharma index of which Divis Laboratories Ltd is a constituent, has eased around 0.81% in last one month and is currently quoting at 26188.4, down 0.23% on the day. The volume in the stock stood at 5.56 lakh shares today, compared to the daily average of 4.44 lakh shares in last one month.
The benchmark September futures contract for the stock is quoting at Rs 9126.5, down 0.75% on the day. Divis Laboratories Ltd jumped 50.52% in last one year as compared to a 8.14% slide in NIFTY and a 17.48% spurt in the Nifty Pharma index.
The PE of the stock is 81.44 based on TTM earnings ending June 26.
Revenue from operations grew 27.80% YoY to Rs 3,080 crore in Q1 FY27 from Rs 2,410 crore in Q1 FY26.
Profit before tax (PBT) stood at Rs 1,180 crore, up 60.98% YoY from Rs 733 crore in the corresponding quarter last year.
Total expenses rose 9.35% YoY to Rs 1,964 crore in Q1 FY27. The cost of materials consumed increased 48.81% YoY to Rs 1,503 crore, while employee benefit expenses rose 20% YoY to Rs 408 crore.
On a standalone basis, the company reported a 59.96% YoY increase in net profit to Rs 891 crore for the quarter ended 30 June 2026, compared with Rs 557 crore in the corresponding quarter last year. Total income rose 22.66% YoY to Rs 3,037 crore in Q1 FY27 from Rs 2,476 crore in Q1 FY26.
The board approved the appointment of B. Vara Prasad, General Manager (Engineering Purchase), and J. Srinivasa Rao, General Manager (Raw Materials Purchase), as Senior Management Personnel with effect from 1 August 2026.
Vara Prasad has been associated with the company since 1994 and has over 31 years of experience in the pharmaceutical industry. He oversees engineering-related procurement and has expertise in strategic sourcing, vendor management, contract negotiations, capital equipment procurement, and execution of large-scale manufacturing projects.
Srinivasa Rao joined the company in 1995 and has over 30 years of experience in pharmaceutical procurement. He is responsible for end-to-end raw material sourcing and has expertise in strategic sourcing, vendor development, contract negotiations, regulatory compliance, and supply chain management.